Learn About Eosinophilic Pneumonia

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Eosinophilic Pneumonia Local Doctors?
Learn about our expert tiers
Learn more
What are the Latest Advances for Eosinophilic Pneumonia?
Benralizumab in the management of rare primary eosinophilic lung diseases.
Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma.
Tired of the same old research?
Check Latest Advances
Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study.
What are the latest Eosinophilic Pneumonia Clinical Trials?
The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma

Summary: The IRIS study aims to investigate the way Mepolizumab affects the structure of the airway cells in patients with Severe Eosinophilic Asthma and how the immune function of these cells changes with treatment. The aim is to take samples of cells from the airways before starting Mepolizumab and after 6 months of treatment. These samples will be taken during a bronchoscopy (a camera test looking into ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation: a Double-blind, Randomized, Controlled Trial

Summary: The primary objective of this study is to compare treatment failure rates between a group of eosinophilic (eosinophilia > 2% on day 1 of hospitalization) patients hospitalised for a COPD exacerbation treated via corticotherapy versus a similar group treated via placebo. Secondarily, treatment failure rates will also be compared between a group of non-eosinophilic patients hospitalised for a COPD e...